PCAB Accreditation: What It Actually Means When a Compounding Pharmacy Has It (and Doesn't)

Compounded GLP-1 telehealth providers love to advertise that their fulfillment pharmacy has PCAB accreditation. The acronym gets dropped on landing pages, in checkout flows, and in provider FAQ sections — usually with no explanation of what it actually means or why it matters. This investigation walks through the PCAB program in plain language, explains how it relates to (and differs from) FDA 503B registration, USP 797 compliance, NABP verification, and state board licensure, and gives patients the specific questions to ask any compounded GLP-1 provider before placing a first order. We've also published the PCAB status of every pharmacy in the Weight Loss Rankings database below.

What PCAB actually is

PCAB stands for the Pharmacy Compounding Accreditation Board. It is operated by the Accreditation Commission for Health Care (ACHC), a third-party non-profit accreditor. PCAB accreditation is a voluntary credential — no federal law requires a 503A compounding pharmacy to have it, and no state licensure board mandates it. A pharmacy applies, pays an inspection fee, undergoes an on-site quality audit against PCAB's published standards (which are aligned with USP General Chapters <795> and <797>), and either receives accreditation or is required to remediate the cited deficiencies before receiving it [1].

Re-accreditation typically occurs every three years, with unannounced surveys possible in the interim. PCAB's scope covers personnel training, facility design, equipment, environmental monitoring, sterile and non-sterile compounding processes, batch documentation, beyond-use dating, and complaint handling. It is the most-recognized voluntary quality program for 503A compounding pharmacies in the US.

The credentials hierarchy patients should understand

PCAB is one rung in a multi-level system. Here's how the whole stack actually works:

What PCAB does NOT verify

This is the part patients almost never hear:

1. PCAB does not verify the active pharmaceutical ingredient (API) source. A PCAB-accredited pharmacy can — and often does — purchase API from third-party suppliers whose own quality systems are not audited as part of the PCAB process. The pharmacy is responsible for ingredient verification, but PCAB inspectors do not independently test the API lot.
2. PCAB does not run independent batch potency or purity testing on the finished compounded product. The pharmacy may run its own batch testing (and good ones do), but third-party lab verification is not part of the PCAB process.
3. PCAB does not enforce compounding limits on drugs that have not been approved by the FDA. For example, compounded retatrutide is not eligible under section 503A (it's an investigational molecule), but PCAB accreditation alone does not stop a pharmacy from compounding it. Whether a pharmacy actually does so is a separate question of regulatory compliance, and FDA enforcement covers that gap.
4. PCAB does not verify telehealth provider claims about which pharmacy fulfills their orders. A telehealth company can advertise that they use a PCAB-accredited pharmacy and then ship orders through a different, non-accredited pharmacy. This is a documented enforcement issue — see our FDA warning letters investigation for examples.

The 503A vs 503B distinction matters more than PCAB

For compounded GLP-1s specifically, the most important credential is not PCAB — it's whether the pharmacy is a section 503A traditional compounder or a section 503B outsourcing facility. The two operate under fundamentally different rules [4]:

• 503A: Patient-specific prescriptions only. Cannot manufacture in advance for sale to other entities. Subject to USP standards and state board oversight, but not to FDA cGMP enforcement. Most compounding pharmacies in the US are 503A.
• 503B (outsourcing facility): Can produce drugs without patient-specific prescriptions for sale to healthcare entities. Must register with the FDA, must comply with cGMP (the same standard branded manufacturers meet), subject to direct FDA inspection, must report adverse events to FDA, and must use only API from FDA-registered facilities.

503B is a substantially higher quality bar than 503A, and a substantially higher bar than PCAB accreditation alone. A 503B-registered facility that is also PCAB-accredited is the highest quality combination available for compounded GLP-1s in the US. For the bioequivalence and quality differences, see our compounded semaglutide bioequivalence deep-dive.

PCAB status of every pharmacy in our database

We track 13 compounding pharmacies that fulfill GLP-1 orders for telehealth providers in the Weight Loss Rankings marketplace. Of those, 11 are PCAB-accredited and 2 are also FDA 503B outsourcing facilities (the highest tier). The remaining 2 are state-licensed but not PCAB- accredited at the time of our last verification.

These numbers update automatically as our pharmacy database is verified and refreshed. The full pharmacy directory contains additional detail on each facility, including states licensed, drug menu, and any documented regulatory actions.

Specific questions to ask a compounded GLP-1 provider

Before placing a first order with any compounded GLP-1 telehealth provider, ask the following — and get answers in writing:

1. Which specific pharmacy fulfills my prescription, and is it PCAB-accredited? Ask for the pharmacy's legal name and physical address. Verify that the name matches a known PCAB-accredited facility on the ACHC public directory.
2. Is the pharmacy a 503A or a 503B? 503B is a higher quality tier with cGMP enforcement and direct FDA oversight. 503A is the more common patient-specific model.
3. Does the pharmacy run third-party batch potency and sterility testing? A pharmacy that performs independent batch testing through a separate accredited analytical lab is providing a quality signal that PCAB accreditation alone does not.
4. Where does the API come from, and is the supplier FDA-registered? For 503B facilities, the API must come from an FDA-registered manufacturer. For 503A facilities the rules are looser, but a serious pharmacy should be able to name its API supplier.
5. Has the pharmacy received any FDA warning letters in the past three years? Cross-check against our FDA warning letters database. A warning letter does not automatically disqualify a pharmacy — many remediate cited issues — but it tells you what to ask about.
6. What is the form of the active ingredient? Specifically: is it the semaglutide base molecule, or a salt form (sodium or acetate)? Salt forms are not the same active ingredient as the base molecule used in FDA-approved semaglutide products, and FDA has flagged salt-form sourcing as a quality concern in the warning letter program.

What this means for patients

PCAB accreditation is a meaningful quality signal for a 503A compounding pharmacy. It says the facility has been independently audited against published standards by a non-profit third party and has chosen to subject itself to ongoing oversight that is not legally required. That is not nothing — and a pharmacy without PCAB accreditation is meaningfully harder to evaluate from the outside.

But PCAB accreditation is not a substitute for the harder questions: API source, batch testing, salt-form vs base molecule, regulatory history, and which legal compounding category the pharmacy operates under. The patients who get burned by compounded GLP-1s almost never get burned because their pharmacy lacked PCAB accreditation. They get burned because the API was sourced from an unverified supplier, because the salt form differed from the FDA-approved base molecule, because the dosing was wrong, or because the telehealth provider routed their prescription through a different pharmacy than the one they advertised.

Use PCAB as a screening filter, not a final answer. Combine it with the 503A vs 503B distinction, the questions above, and our FDA warning letter cross-check to build a complete picture before placing an order.

Related research

For the broader compounded GLP-1 quality and regulatory landscape, see our compounded semaglutide bioequivalence investigation, our FDA warning letters database, and our floor-price provider verification. For context on the specific drugs being compounded, see the Wegovy pen vs compounded vial practical comparison.